NASDAQ:INFI

Infinity Pharmaceuticals Stock Forecast, Price & News

$3.31
-0.15 (-4.34 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.28
Now: $3.31
$3.46
50-Day Range
$2.60
MA: $3.24
$3.83
52-Week Range
$0.78
Now: $3.31
$5.98
Volume972,793 shs
Average Volume3.82 million shs
Market Capitalization$293.40 million
P/E RatioN/A
Dividend YieldN/A
Beta2.4
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000
Employees25
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.05 million
Book Value$0.14 per share

Profitability

Net Income$-47,060,000.00
Net Margins-2,592.65%

Miscellaneous

Market Cap$293.40 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

Infinity Pharmaceuticals (NASDAQ:INFI) Now Covered by Truist
March 18, 2021 |  americanbankingnews.com
Infinity Pharmaceuticals (NASDAQ:INFI) Shares Gap Down to $3.10
March 17, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

421st out of 2,010 stocks

Pharmaceutical Preparations Industry

202nd out of 769 stocks

Analyst Opinion: 4.4Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$3.31
-0.15 (-4.34 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

Is Infinity Pharmaceuticals a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Infinity Pharmaceuticals?

Wall Street analysts have given Infinity Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Infinity Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a increase in short interest in February. As of February 26th, there was short interest totaling 1,240,000 shares, an increase of 115.5% from the February 11th total of 575,400 shares. Based on an average daily volume of 3,670,000 shares, the days-to-cover ratio is presently 0.3 days.
View Infinity Pharmaceuticals' Short Interest
.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Infinity Pharmaceuticals
.

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its earnings results on Monday, March, 15th. The biotechnology company reported ($0.16) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.16). Infinity Pharmaceuticals had a negative net margin of 2,592.65% and a negative trailing twelve-month return on equity of 1,358.77%.
View Infinity Pharmaceuticals' earnings history
.

How has Infinity Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INFI stock has increased by 227.7% and is now trading at $3.31.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for INFI?

8 equities research analysts have issued 1 year price targets for Infinity Pharmaceuticals' shares. Their forecasts range from $4.00 to $12.00. On average, they anticipate Infinity Pharmaceuticals' share price to reach $9.00 in the next year. This suggests a possible upside of 171.9% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 61, Pay $1.13M)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 55, Pay $701.62k)
  • Dr. Jeffery L. Kutok, Chairman of Scientific Advisory Board (Age 54, Pay $606.87k)
  • Ms. Melissa Hackel, VP of Fin.
  • Mr. Seth A. Tasker, Chief Bus. Officer (Age 42)
  • Ms. Rossitza Alargova Ph.D., Head of Pharmaceutical Devel.
  • Dr. Brian Schwartz, Consulting Chief Physician (Age 59)
  • Jayne Kauffman, Sr. Exec. Coordinator

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Infinity Pharmaceuticals' key competitors?

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $3.31.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals has a market capitalization of $293.40 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Infinity Pharmaceuticals have?

Infinity Pharmaceuticals employs 25 workers across the globe.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is www.infi.com.

Where are Infinity Pharmaceuticals' headquarters?

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.